{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:23:05Z","timestamp":1787739785494,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["TJ2021-0111"],"award-info":[{"award-number":["TJ2021-0111"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["PR2022-0071"],"award-info":[{"award-number":["PR2022-0071"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008738","name":"Jeanssons Stiftelser","doi-asserted-by":"publisher","award":["No."],"award-info":[{"award-number":["No."]}],"id":[{"id":"10.13039\/100008738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r Strategisk Forskning","doi-asserted-by":"publisher","award":["CMP22-0014"],"award-info":[{"award-number":["CMP22-0014"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Amplification of the MYCN proto-oncogene serves as a key marker of aggressive disease and poor treatment outcomes in certain pediatric tumors originating from the nervous system, including neuroblastoma and medulloblastoma. However, the complex nature of the challenging MYCN protein underscores the urgent need for additional targets and therapies to tackle neuroblastoma and medulloblastoma. In this study, with a primary focus on neuroblastoma and the aim of also benefiting children with medulloblastoma, we identified FLIX5, a small compound that exhibits broad cytotoxicity against both neuroblastoma and medulloblastoma cells, primarily by triggering apoptosis. Furthermore, FLIX5 enhances the cholesterol dependency of neuroblastoma cells under conditions where mitochondrial function is impaired. FLIX5 as well shows a synergistic effect when combined with vincristine, a conventional anticancer drug, against neuroblastoma cells and organoids. Through proteome integral solubility alteration, computational molecular docking predictions, and cellular thermal shift assays for target identification and validation, FLIX5 reveals EPLIN (Epithelial Protein Lost In Neoplasm) as a previously unexplored drug target. EPLIN is involved in several cellular processes, including cholesterol uptake and mitochondrial function. The discovery of FLIX5 targeting EPLIN presents new opportunities for treating malignant pediatric tumors, with the potential to target chemoresistant dormant cancer cells and broaden its therapeutic applications to other tumor types.<\/jats:p>","DOI":"10.1038\/s41419-025-07876-7","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:16:46Z","timestamp":1753309006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2785-946X","authenticated-orcid":false,"given":"Emma","family":"Lindell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-3877","authenticated-orcid":false,"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-1177","authenticated-orcid":false,"given":"Miao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natallia","family":"Rameika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Svanberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azazul I.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bergsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5657-2839","authenticated-orcid":false,"given":"Xingqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bexell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8460-4367","authenticated-orcid":false,"given":"Fredrik J.","family":"Swartling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-4140","authenticated-orcid":false,"given":"Tobias","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-9079","authenticated-orcid":false,"given":"Xiaonan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"7876_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"7876_CR2","first-page":"4248","volume":"47","author":"GM Brodeur","year":"1987","unstructured":"Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res. 1987;47:4248\u201353.","journal-title":"Cancer Res"},{"key":"7876_CR3","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202\u201311.","journal-title":"N Engl J Med"},{"key":"7876_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/neuonc\/noae178","volume":"27","author":"EC Schwalbe","year":"2025","unstructured":"Schwalbe EC, Lindsey JC, Danilenko M, Hill RM, Crosier S, Ryan SL, et al. Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study. Neuro Oncol. 2025;27:222\u201336.","journal-title":"Neuro Oncol"},{"key":"7876_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1040-8428(00)00077-9","volume":"36","author":"BatesRC Edwards","year":"2000","unstructured":"Edwards BatesRC, Yates NS. JD. Spheroids and cell survival. Crit Rev Oncol\/Hematol. 2000;36:61\u201374.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"7876_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1023\/A:1016249728664","volume":"20","author":"M Hagg","year":"2002","unstructured":"Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Investigational N drugs. 2002;20:253\u20139.","journal-title":"Investigational N drugs"},{"key":"7876_CR7","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.actbio.2010.01.038","volume":"6","author":"P Davidson","year":"2010","unstructured":"Davidson P, Bigerelle M, Bounichane B, Giazzon M, Anselme K. Definition of a simple statistical parameter for the quantification of orientation in two dimensions: application to cells on grooves of nanometric depths. Acta biomaterialia. 2010;6:2590\u20138.","journal-title":"Acta biomaterialia"},{"key":"7876_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/1087057104265040","volume":"9","author":"LA Kunz-Schughart","year":"2004","unstructured":"Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J biomolecular Screen. 2004;9:273\u201385.","journal-title":"J biomolecular Screen"},{"key":"7876_CR9","doi-asserted-by":"publisher","unstructured":"Lindell E, Zhang X. Exploring the enigma: the role of the epithelial protein lost in neoplasm in normal physiology and cancer pathogenesis. Int J Mol Sci. 2024;25,4970 https:\/\/doi.org\/10.3390\/ijms25094970.","DOI":"10.3390\/ijms25094970"},{"key":"7876_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36847-9","volume":"14","author":"OJ Mainwaring","year":"2023","unstructured":"Mainwaring OJ, Weishaupt H, Zhao M, Rosen G, Borgenvik A, Breinschmid L, et al. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. Nat Commun. 2023;14:1221.","journal-title":"Nat Commun"},{"key":"7876_CR11","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-22-2108","volume":"82","author":"A Borgenvik","year":"2022","unstructured":"Borgenvik A, Holmberg KO, Bolin S, Zhao M, Savov V, Rosen G, et al. Dormant SOX9-positive cells facilitate MYC-driven recurrence of medulloblastoma. Cancer Res. 2022;82:4586\u2013603.","journal-title":"Cancer Res"},{"key":"7876_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"7876_CR13","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1021\/acs.jproteome.9b00500","volume":"18","author":"M Gaetani","year":"2019","unstructured":"Gaetani M, Sabatier P, Saei AA, Beusch CM, Yang Z, Lundstrom SL, et al. Proteome integral solubility alteration: a high-throughput proteomics assay for target deconvolution. J Proteome Res. 2019;18:4027\u201337.","journal-title":"J Proteome Res"},{"key":"7876_CR14","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100\u201322.","journal-title":"Nat Protoc"},{"key":"7876_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","volume":"14","author":"MN Prichard","year":"1990","unstructured":"Prichard MN, Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. Antivir Res. 1990;14:181\u2013205.","journal-title":"Antivir Res"},{"key":"7876_CR16","doi-asserted-by":"publisher","first-page":"e85771","DOI":"10.1371\/journal.pone.0085771","volume":"9","author":"L Chen","year":"2014","unstructured":"Chen L, Ye HL, Zhang G, Yao WM, Chen XZ, Zhang FC, et al. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PLoS One. 2014;9:e85771.","journal-title":"PLoS One"},{"key":"7876_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049.","journal-title":"Nat Commun"},{"key":"7876_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 2019;8:329\u201337.e4.","journal-title":"Cell Syst"},{"key":"7876_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495\u2013502.","journal-title":"Nat Biotechnol"},{"key":"7876_CR20","doi-asserted-by":"crossref","unstructured":"Hansson K, Radke K, Aaltonen K, Saarela J, Manas A, Sjolund J, et al. Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma. Sci Transl Med. 2020;12:eaba4434.","DOI":"10.1126\/scitranslmed.aba4434"},{"key":"7876_CR21","doi-asserted-by":"publisher","first-page":"E252","DOI":"10.1002\/ijc.29217","volume":"136","author":"N Braekeveldt","year":"2015","unstructured":"Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer. 2015;136:E252\u201361.","journal-title":"Int J Cancer"},{"key":"7876_CR22","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u2013W93.","journal-title":"Nucleic Acids Res"},{"key":"7876_CR23","first-page":"6185","volume":"61","author":"N Keshelava","year":"2001","unstructured":"Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001;61:6185\u201393.","journal-title":"Cancer Res"},{"key":"7876_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-0716-2624-5_7","volume":"2554","author":"M Gaetani","year":"2023","unstructured":"Gaetani M, Zubarev RA. Proteome integral solubility alteration (PISA) for high-throughput ligand target deconvolution with increased statistical significance and reduced sample amount. Methods Mol Biol. 2023;2554:91\u2013106.","journal-title":"Methods Mol Biol"},{"key":"7876_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28139-5","volume":"13","author":"B Duethorn","year":"2022","unstructured":"Duethorn B, Groll F, Rieger B, Drexler HCA, Brinkmann H, Kremer L, et al. Lima1 mediates the pluripotency control of membrane dynamics and cellular metabolism. Nat Commun. 2022;13:610.","journal-title":"Nat Commun"},{"key":"7876_CR26","doi-asserted-by":"publisher","first-page":"7838","DOI":"10.1038\/sj.onc.1203206","volume":"18","author":"RS Maul","year":"1999","unstructured":"Maul RS, Chang DD. EPLIN, epithelial protein lost in neoplasm. Oncogene. 1999;18:7838\u201341.","journal-title":"Oncogene"},{"key":"7876_CR27","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1474-4422(15)00148-9","volume":"14","author":"G Zsurka","year":"2015","unstructured":"Zsurka G, Kunz WS. Mitochondrial dysfunction and seizures: the neuronal energy crisis. Lancet Neurol. 2015;14:956\u201366.","journal-title":"Lancet Neurol"},{"key":"7876_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4295","volume":"5","author":"X Zhang","year":"2014","unstructured":"Zhang X, Fryknas M, Hernlund E, Fayad W, De Milito A, Olofsson MH, et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 2014;5:3295.","journal-title":"Nat Commun"},{"key":"7876_CR29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1126\/science.aao6575","volume":"360","author":"YY Zhang","year":"2018","unstructured":"Zhang YY, Fu ZY, Wei J, Qi W, Baituola G, Luo J, et al. A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption. Science. 2018;360:1087\u201392.","journal-title":"Science"},{"key":"7876_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.819281","volume":"10","author":"Q Shi","year":"2022","unstructured":"Shi Q, Chen J, Zou X, Tang X. Intracellular Cholesterol Synthesis and Transport. Front Cell Dev Biol. 2022;10:819281.","journal-title":"Front Cell Dev Biol"},{"key":"7876_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44862-7","volume":"15","author":"MA Klein","year":"2024","unstructured":"Klein MA, Wild K, Kisonaite M, Sinning I. Methionine aminopeptidase 2 and its autoproteolysis product have different binding sites on the ribosome. Nat Commun. 2024;15:716.","journal-title":"Nat Commun"},{"key":"7876_CR32","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.tips.2021.07.004","volume":"42","author":"A Goya Grocin","year":"2021","unstructured":"Goya Grocin A, Kallemeijn WW, Tate EW. Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity. Trends Pharm Sci. 2021;42:870\u201382.","journal-title":"Trends Pharm Sci"},{"key":"7876_CR33","doi-asserted-by":"crossref","unstructured":"McIntosh JR. Mitosis. Cold Spring Harb Perspect biol. 2016;8:a023218.","DOI":"10.1101\/cshperspect.a023218"},{"key":"7876_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1349-7006.2005.00062.x","volume":"96","author":"D Yamazaki","year":"2005","unstructured":"Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005;96:379\u201386.","journal-title":"Cancer Sci"},{"key":"7876_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fphar.2020.00042","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Hua Y, Li X, Arslan IM, Zhang W, Meng G. Distinct types of cell death and the implication in diabetic cardiomyopathy. Front Pharm. 2020;11:42.","journal-title":"Front Pharm"},{"key":"7876_CR36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929\u201335.","journal-title":"Science"},{"key":"7876_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06511-1","volume":"15","author":"YW Guo","year":"2024","unstructured":"Guo YW, Zhu L, Duan YT, Hu YQ, Li LB, Fan WJ, et al. Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission. Cell Death Dis. 2024;15:125.","journal-title":"Cell Death Dis"},{"key":"7876_CR38","first-page":"1034","volume":"39","author":"N Zhang","year":"2018","unstructured":"Zhang N, Qiu J, Zheng T, Zhang X, Hua K, Zhang Y. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K\/AKT signaling pathway. Oncol Rep. 2018;39:1034\u201342.","journal-title":"Oncol Rep"},{"key":"7876_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109778","volume":"352","author":"HY Lee","year":"2022","unstructured":"Lee HY, Tang DW, Liu CY, Cho EC. A novel HDAC1\/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation. Chem Biol Interact. 2022;352:109778.","journal-title":"Chem Biol Interact"},{"key":"7876_CR40","doi-asserted-by":"publisher","first-page":"90225","DOI":"10.18632\/oncotarget.21653","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Mofers A, Hydbring P, Olofsson MH, Guo J, Linder S, et al. MYC is downregulated by a mitochondrial checkpoint mechanism. Oncotarget. 2017;8:90225\u201337.","journal-title":"Oncotarget"},{"key":"7876_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2016.12.034","volume":"390","author":"T Ohashi","year":"2017","unstructured":"Ohashi T, Idogawa M, Sasaki Y, Tokino T. p53 mediates the suppression of cancer cell invasion by inducing LIMA1\/EPLIN. Cancer Lett. 2017;390:58\u201366.","journal-title":"Cancer Lett"},{"key":"7876_CR42","doi-asserted-by":"publisher","first-page":"e0115635","DOI":"10.1371\/journal.pone.0115635","volume":"10","author":"M Richter","year":"2015","unstructured":"Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, et al. WIP1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One. 2015;10:e0115635.","journal-title":"PLoS One"},{"key":"7876_CR43","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.1994.12.12.2607","volume":"12","author":"BH Kushner","year":"1994","unstructured":"Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994;12:2607\u201313.","journal-title":"J Clin Oncol"},{"key":"7876_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09662-8","volume":"7","author":"CU Persson","year":"2017","unstructured":"Persson CU, von Stedingk K, Bexell D, Merselius M, Braekeveldt N, Gisselsson D, et al. Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum. Sci Rep. 2017;7:10274.","journal-title":"Sci Rep"},{"key":"7876_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature11327","volume":"488","author":"PA Northcott","year":"2012","unstructured":"Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488:49\u201356.","journal-title":"Nature"},{"key":"7876_CR46","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1101\/gad.1907510","volume":"24","author":"FJ Swartling","year":"2010","unstructured":"Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010;24:1059\u201372.","journal-title":"Genes Dev"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07876-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07876-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07876-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:09:12Z","timestamp":1757286552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07876-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7876"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07876-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Neuroblastoma PDX-derived cells LU-NB-1 and LU-NB-2, obtained from Professor Daniel Bexell (ethic approve ref. no. 2016\/1055, 2018\/155). All methods were performed in accordance with the relevant guidelines and regulations. This study did not include any animal work. This study did not include human research participants. No remaining ethical issues warrant consideration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"554"}}